Kyowa Hakko Kirin California, Inc. (KKC) is a wholly-owned US subsidiary of Kyowa Hakko Kirin Co., Ltd. KKC serves as one of Kyowa Hakko Kirin's R&D centers in the United States, and facilitates the company's business and product development efforts in North America. We are focused on developing fully human antibody based therapeutics in four major disease areas: oncology, renal diseases, immune disorders and allergy.
Our three-story state-of-the-art facility is located at the University of California San Diego's Science Research Park in La Jolla, California. KKC's scientific staff consists of more than 30 researchers, approximately one third of whom hold doctoral degrees. Our dedicated team is a focused and interactive group involved in pursuing innovative biomedical research and technologies targeted towards the development of novel therapeutics.
Click here to view press release
Kyowa Hakko Kirin announces the initiation of Phase 1-clinical trial of KRN23, a novel IV drug discovered by KHK for the treatment of X-linked Hypophosphatemia (XLH). XLH is a genetic metabolic condition which affects bone and teeth development.
As of January 1, 2009, Kirin Pharma USA has changed its name to Kyowa Hakko Kirin California, Inc.
(For more news releases, click here)
